Ethical implications of race and genomics - Racializing drug design: Implications of pharmacogenomics
Ethical implications of race and genomics - Racializing drug design: Implications of pharmacogenomics
复制标题
DOI：
10.2105/ajph.2005.068676
复制
发表时间：
2005-12-01
影响因子：
12.7
通讯作者：
Lee, SSJ
中科院分区：
文献类型：
--
作者：
Lee, SSJ
在药物基因组学研究中使用“种族”的现行做法要求考虑对理解群体差异和消除健康差异的努力的伦理和社会影响。本讨论的重点是“种族化的基础设施”，目前的研究轨迹之间的遗传差异的种族确定的群体，使用种族作为一个代理的风险在临床实践中，越来越多的兴趣，在新的市场利基的制药行业，这些因素的汇合，导致了基因，疾病和种族的混淆。我认为，在药物基因组学的公共投资需要仔细考虑目前的不平等，在健康状况和社会和道德问题的具体化种族和分配正义的问题。
Current practices of using "race" in pharmacogenomics research demands consideration of the ethical and social implications for understandings of group difference an for efforts to eliminate health disparities. This discussion focuses on an "infrastructure of racialization" created by current trajectories of research on genetic differences among racially identified groups, the use of race as a proxy for risk in clinical practice, and increasing interest in new market niches by the pharmaceutical industry.The confluence of these factors has resulted in the conflation of genes, disease, and race. I argue that public investment in pharmacogenomics requires careful consideration of current inequities in health status and social and ethical concerns over reifying race and issues of distributive justice.